HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Shanghai Pulse Medical Technology - The Industry, the Business and the Concerns

Pre-IPO Beijing Yuanxin Technology Group - Conservative About the Outlook

JD Health (6618.HK) - Logic Change Due to the New Policy?

Pre-IPO MicroPort NeuroTech - The Industry, the Business and the Concern

Gravity Works As WeWork Doesn't; Now Plan B

Equity Capital Markets

<ul>
<li>The combination of FFR and IMR can provide a complete functional evaluation from epicardial arteries to myocardial microcirculation,pushing the precise diagnosis and treatment of coronary disease into a new era.</li>
<li>Rainmed’s caFFR System and caIMR System have obvious technical and first-mover advantages; The CE certificate also opens up the imagination space of product commercialization (such as developing markets).</li>
<li>However, the concerns on current sales model, market acceptance, medical insurance coverage, cash flow pressure and market sentiment when IPO should also not be neglected. </li>
</ul>


The combination of FFR and IMR can provide a complete functional evaluation from epicardial arteries to myocardial microcirculation,pushing the precise diagnosis and treatment of coronary disease into a new era.
Rainmed’s caFFR System and caIMR System have obvious technical and first-mover advantages; The CE certificate also opens up the imagination space of product commercialization (such as developing markets).
However, the concerns on current sales model, market acceptance, medical insurance coverage, cash flow pressure and market sentiment when IPO should also not be neglected. 


Pre-IPO Rainmed Medical - The Industry, the Business and the Concerns